Blue-blocking Glasses for Sleep Disorders in Child and Adolescent Psychiatry

Starting soon · Not applicable

Conditions studied: Insomnia, Delayed Sleep Phase Disorder, Hyperarousal, Transdiagnostic Psychopathology, Child and Adolescent Psychiatry

In brief

Sleep problems and regulation difficulties are frequent in the child and adolescent psychiatry population. Insomnia and delayed sleep-wake phase disorders (DSPWD) are highly prevalent, and risk factors for developing more severe illness courses and chronic disorders. Pharmacological treatments of sleep disorders dominate even for the youngest patients but are unsupported by long-term data on outcome and side effects. The majority of non-pharmacological treatment options are composite and resource demanding. The investigators will examine the effects and feasibility of the isolated intervention of evening/night use of blue-blocking glasses/real darkness as adjunctive treatment for insomnia and delayed sleep phase disorder in inpatient and outpatient settings for children and adolecents.

Key facts

Study ID

NCT07433491

Run by

Helse Fonna

People needed

40

Starts

2026-02-01

Expected to finish

2027-06-01

Last updated by the study team

2026-02-25

Who can join

Age: 12 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 12-18 years, receiving health-care from child and adolescent mental health services at UPA University Hospital of North Norway, Tromsø or BUP Haugesund Hospital, Haugesund
• Current Insomnia or DSPD comorbid to one or several pychiatric symptom presentations or diagnoses
• Able and willing to provide written informed consent
• Participants aged 12-15,9 years also need consent from both parents/carers
• Able to comply with protocol
• Able to discontinue melatonin or BB-glasses if currently used, with at least 3 days washout period

You may not qualify if…

• Not able to comply with protocol for a required minimum of one night
• Blindness or severely reduced translucency of both eyes
• Known malformation or damage of optical tract blindness
• Use of melatonin all formulas that cannot be paused
• High risk for suicide or self-harm
• Consent from both partents/carers unlikely (participants age 12-15,9 years)

Where it is running

• BUP Haugesund — Haugesund, Rogaland, Norway
• BUPA Tromsø, The University Hospital of North Norway — Tromsø, Troms, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.